NCT05868382

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 270 (actual)
• Sponsor: ModernaTX, Inc. · Industry
• Sex: All
• Age: 18 Years – 49 Years
• Healthy volunteers: Accepted

Summary

The main purpose of the study is to evaluate the safety, reactogenicity, and the immunogenicity of mRNA-1010 vaccine candidate variations.

Conditions

• Influenza

Interventions

Type	Name	Description
BIOLOGICAL	mRNA-1010	Sterile liquid for injection
BIOLOGICAL	mRNA-1010.4	Sterile liquid for injection
BIOLOGICAL	mRNA-1010.6	Sterile liquid for injection

Timeline

• Start date: 2023-05-15
• Primary completion: 2023-12-19
• Completion: 2023-12-19
• First posted: 2023-05-22
• Last updated: 2024-12-20
• Results posted: 2024-12-20

Locations

10 sites across 1 country: United States

Regulatory

• FDA-regulated drug study